Merck KGaA's pending Silence deal lands as divesiran data de-risk an RNAi asset

What happened

Silence Therapeutics reported a third-quarter loss of $12.4M and cash of $247.7M. The results sit alongside two things that matter more: positive Phase 2 data for divesiran in polycythemia vera, and the pending acquisition of the company by Merck KGaA.

The material available to us does not give the deal terms, the expected closing timetable or the conditions attached, so this analysis does not assess price or premium. What can be said is that the quarterly financials are now a secondary story. Silence reported as a company in the middle of a transaction, with a clinical readout that supports its lead asset's case.

The strategic logic

For an acquirer, the attraction of an RNAi company with positive mid-stage data in a defined haematology indication is straightforward. Phase 2 efficacy evidence converts a platform story into an asset story, and the cash balance means Silence is not selling from weakness. A company holding $247.7M and a positive readout negotiates from a different position than one racing a funding deadline.

The timing of the data and the pending deal is also notable. The data sit alongside the transaction rather than ahead of it, so the Phase 2 result is best read as the asset the acquirer has underwritten, not as a catalyst that could still change the terms. The remaining questions are about execution and closing, not about whether the science has been tested.

A bifurcated deal market

The same day's news flow shows how wide the gap is between assets that attract strategic capital and those that do not.

Longeveron said laromestrocel missed its primary endpoint in infants with hypoplastic left heart syndrome. It is seeking an FDA meeting and has started a strategic alternatives review that could end in a sale or merger. Theriva Biologics sold its SYN-004 antibiotic-enzyme assets to Biossil Labs for $350,000 upfront, a small sum that suggests how little value a non-core asset can command when a company is concentrating on its lead programme. Theriva expects VIRAGE2 enrolment in metastatic pancreatic cancer to finish in the fourth quarter of 2026.

Further up the value chain, Gedeon Richter licensed estetrol combination rights to Eli Lilly worldwide. Lilly gets exclusive development rights in women's health and cardiometabolic disease, a US co-commercialisation option on Richter's FYLREVY, and will buy about $15M of Richter shares. Kiora in-licensed rights outside Asia to Senju's oral calpain inhibitor KIO-401 (mitucapistat) for retinal artery occlusion and has requested a pre-IND meeting and orphan drug designation. Alcon, reporting nine-month sales of $8.2bn, highlighted its planned purchase of Neurotech Pharmaceuticals.

Taken together, the pattern is clear. Capital is flowing to assets with data, a defined indication or a regulatory pathway, whether by acquisition, licence or equity-linked partnership. Programmes that miss endpoints, or that sit outside a company's core focus, are being sold cheaply or put under review.

Risks

The first risk is deal execution. With terms and conditions absent from our material, closing timing, regulatory clearances and shareholder approvals remain open variables. Merger review is not trivial: the UK CMA's Phase 1 review of AkzoNobel-Axalta, which found concerns only in UK vehicle refinish coatings, shows how a competition authority can narrow its objections to one market and how the companies can respond with a pre-agreed divestment. That is a coatings case, not a pharma one, but it illustrates how remedies are negotiated across jurisdictions.

The second risk is clinical and developmental. A Phase 2 result in polycythemia vera is supportive, not definitive, and the move into later-stage development will test the durability and safety of divesiran. Longeveron's miss is a reminder that positive expectations can fail at the primary endpoint.

The third is the operating burden of an acquired biotech. Silence's $12.4M quarterly loss is modest against its cash, but any acquirer inherits the cost of advancing a programme through registration-enabling work, plus the integration challenge of retaining RNAi expertise.

What to watch

Watch for disclosure of the transaction timetable and closing conditions, and for any regulatory filings. Watch also for how Merck KGaA frames divesiran's development path and its fit within its portfolio. On the broader market, the Longeveron strategic review will show how buyers value a failed late-stage asset, while Alcon's Neurotech purchase and the Lilly-Richter agreement will indicate whether larger companies keep favouring targeted bolt-ons and option-style partnerships over transformational deals.